U.S. drugmaker Regeneron Pharmaceuticals on Thursday reported weaker-than-expected quarterly sales of the higher dose version ...

Truist lowered the firm’s price target on Regeneron (REGN) to $1,126 from $1,137 and keeps a Buy rating on the shares after its Q3 results. Investor focus has been on Eylea and Eylea HD ...

Regeneron Pharmaceuticals ( (REGN)) has released its Q3 earnings. Here is a breakdown of the information Regeneron Pharmaceuticals presented to its investors. Regeneron Pharmaceuticals, Inc. is a ...

With U.S. sales of $392 million in the third quarter, Regeneron’s high-dose version of Eylea is closing in on blockbuster sales in its first full year on the market. The bad news for the company ...

Regeneron showcases robust revenue growth with net product sales increasing from $5,226.2 million to $5,626.3 million in the nine months ended September 30. Collaboration revenue growth signifies ...

Shares of Regeneron (NASDAQ:REGN) lost nearly a third of their value since my previous update where I said that the stock is near the high end of the valuation range that I deemed appropriate to ...

In a report released yesterday, Terence Flynn from Morgan Stanley maintained a Buy rating on Regeneron (REGN – Research Report), with a price target of $1,184.00. Terence Flynn’s rating is ...

Shares of REGN opened at $843.60 on Friday. Regeneron Pharmaceuticals has a twelve month low of $783.57 and a twelve month high of $1,211.20. The stock has a market cap of $93.00 billion, a PE ...

Despite a beat on both top and bottom lines with its Q3 2024 financials, Regeneron Pharmaceuticals (NASDAQ:REGN) lost more than 10% on Thursday, a move BMO Capital Markets attributed to lower-than ...

Barclays lowered the firm’s price target on Regeneron (REGN) to $1,065 from $1,080 and keeps an Overweight rating on the shares post the Q3 report. The firm says recent pressure on Regeneron ...

Regeneron Pharmaceuticals had a return on equity of 16.88% and a net margin of 33.61%. The business had revenue of $3.55 billion for the quarter, compared to analyst estimates of $3.38 billion.